Comparative genomics of NAD(P) biosynthesis and novel antibiotic drug targets

Journal of Cellular Physiology

Volumn 226, Issue 2, 2011, Pages 331-340

  Bi, Jicai ^a   Wang, Honghai ^b   Xie, Jianping ^a,b  

^a SOUTHWEST UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINAMIDE ADENINE DINUCLEOTIDE SYNTHASE; NICOTINIC ACID MONONUCLEOTIDE ADENYLYLTRANSFERASE; UNCLASSIFIED DRUG;

BIOSYNTHESIS; DRUG TARGETING; GENOMICS; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AMIDE SYNTHASES; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; DRUG DESIGN; GENOMICS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; NADP; NICOTINAMIDE MONONUCLEOTIDE; NICOTINAMIDE-NUCLEOTIDE ADENYLYLTRANSFERASE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SEQUENCE ALIGNMENT; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 78649666339     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22419     Document Type: Review

References (86)

1. Allibert P, Willison JC, Vignais PM. 1987. Complementation of nitrogen-regulatory (ntr-like) mutations in Rhodobacter capsulatus by an Escherichia coli gene: Cloning and sequencing of the gene and characterization of the gene product. J Bacteriol 169: 260-271.
2. Apps DK. 1971. Inhibition of pigeon liver NAD kinase by a non-phosphorylatible analogue of NAD. FEBS Lett 15: 277-280.
3. Belenky P, Bogan KL, Brenner C. 2007a. NAD+ metabolism in health and disease. Trends Biochem Sci 32: 12-19.
4. Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, Brenner C. 2007b. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 129: 473-484.
5. Bellinzoni M, Buroni S, Pasca MR, Guglierame P, Arcesi F, De Rossi E, Riccardi G. 2005. Glutamine amidotransferase activity of NAD+ synthetase from Mycobacterium tuberculosis depends on an amino-terminal nitrilase domain. Res Microbiol 156: 173-177.
6. Berger F, Ramirez-Hernandez MH, Ziegler M. 2004. The new life of a centenarian: Signalling functions of NAD(P). Trends Biochem Sci 29: 111-118.
7. Berger F, Lau C, Dahlmann M, Ziegler M. 2005. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 280: 36334-36341.
8. Bieganowski P, Brenner C. 2004. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117: 495-502.
9. Bonnac L, Chen L, Pathak R, Gao G, Ming Q, Bennett E, Felczak K, Kullberg M, Patterson SE, Mazzola F, Magni G, Pankiewicz KW. 2007a. Probing binding requirements of NAD kinase with modified substrate (NAD) analogues. Bioorg Med Chem Lett 17: 1512-1515.
10. Bonnac L, Gao GY, Chen L, Felczak K, Bennett EM, Xu H, Kim T, Liu N, Oh H, Tonge PJ, Pankiewicz KW. 2007b. Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis. Bioorg Med Chem Lett 17: 4588-4591.
11. Boshoff HI, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park TH, Yun CS, Schnappinger D, Ehrt S, Williams KJ, Barry CE III. 2008. Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem 283: 19329-19341.
12. Cantoni R, Branzoni M, Labo M, Rizzi M, Riccardi G. 1998. The MTCY428.08 gene of Mycobacterium tuberculosis codes for NAD+ synthetase. J Bacteriol 180: 3218-3221.
13. Chen L, Gao G, Bonnac L, Wilson DJ, Bennett EM, Jayaram HN, Pankiewicz KW. 2007. Methylenebis(sulfonamide) linked nicotinamide adenine dinucleotide analogue as an inosine monophosphate dehydrogenase inhibitor. Bioorg Med Chem Lett 17: 3152-3155.
14. Daniel TM. 2006. The history of tuberculosis. Respir Med 100: 1862-1870.
15. De Lay N, Gottesman S. 2009. The Crp-activated small noncoding regulatory RNA CyaR (RyeE) links nutritional status to group behavior. J Bacteriol 191: 461-476.
16. Denu JM. 2003. Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent deacetylases. Trends Biochem Sci 28: 41-48.
17. Foster JW, Moat AG. 1980. Nicotinamide adenine dinucleotide biosynthesis and pyridine nucleotide cycle metabolism in microbial systems. Microbiol Rev 44: 83-105.
18. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. 2003. Tuberculosis. Lancet 362: 887-899.
19. Gao XF, Li J, Yang ZW, Li YP. 2009. Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: A systematic review. Int J Tuberc Lung Dis 13: 810-819.
20. Garavaglia S, D'Angelo I, Emanuelli M, Carnevali F, Pierella F, Magni G, Rizzi M. 2002. Structure of human NMN adenylyltransferase. A key nuclear enzyme for NAD homeostasis. J Biol Chem 277: 8524-8530.
21. Gazzaniga F, Stebbins R, Chang SZ, McPeek MA, Brenner C. 2009. Microbial NAD metabolism: Lessons from comparative genomics. Microbiol Mol Biol Rev 73: 529-541.
22. Gerdes SY, Scholle MD, D'Souza M, Bernal A, Baev MV, Farrell M, Kurnasov OV, Daugherty MD, Mseeh F, Polanuyer BM, Campbell JW, Anantha S, Shatalin KY, Chowdhury SA, Fonstein MY, Osterman AL. 2002. From genetic footprinting to antimicrobial drug targets: Examples in cofactor biosynthetic pathways. J Bacteriol 184: 4555-4572.
23. Gerdes SY, Kurnasov OV, Shatalin K, Polanuyer B, Sloutsky R, Vonstein V, Overbeek R, Osterman AL. 2006. Comparative genomics of NAD biosynthesis in cyanobacteria. J Bacteriol 188: 3012-3023.
24. Gillespie SH. 2002. Evolution of drug resistance in Mycobacterium tuberculosis: Clinical and molecular perspective. Antimicrob Agents Chemother 46: 267-274.
25. Grose JH, Bergthorsson U, Roth JR. 2005. Regulation of NAD synthesis by the trifunctional NadR protein of Salmonella enterica. J Bacteriol 187: 2774-2782.
26. Grose JH, Joss L, Velick SF, Roth JR. 2006. Evidence that feedback inhibition of NAD kinase controls responses to oxidative stress. Proc Natl Acad Sci USA 103: 7601-7606.
27. Han S, Forman MD, Loulakis P, Rosner MH, Xie Z, Wang H, Danley DE, Yuan W, Schafer J, Xu Z. 2006. Crystal structure of nicotinic acid mononucleotide adenylyltransferase from Staphyloccocus aureus: Structural basis for NaAD interaction in functional dimer. J Mol Biol 360: 814-825.
28. Hara N, Yamada K, Terashima M, Osago H, Shimoyama M, Tsuchiya M. 2003. Molecular identification of human glutamine- and ammonia-dependent NAD synthetases. Carbon-nitrogen hydrolase domain confers glutamine dependency. J Biol Chem 278: 10914-10921.
29. Hegymegi-Barakonyi B, Szekely R, Varga Z, Kiss R, Borbely G, Nemeth G, Banhegyi P, Pato J, Greff Z, Horvath Z, Meszaros G, Marosfalvi J, Eros D, Szantai-Kis C, Breza N, Garavaglia S, Perozzi S, Rizzi M, Hafenbradl D, Ko M, Av-Gay Y, Klebl BM, Orfi L, Keri G. 2008. Signalling inhibitors against Mycobacterium tuberculosis-Early days of a new therapeutic concept in tuberculosis. Curr Med Chem 15: 2760-2770.
30. Holley EA, Spector MP, Foster JW. 1985. Regulation of NAD biosynthesis in Salmonella typhimurium: Expression of nad-lac gene fusions and identification of a nad regulatory locus. J Gen Microbiol 131: 2759-2770.
31. Huang N, De Ingeniis J, Galeazzi L, Mancini C, Korostelev YD, Rakhmaninova AB, Gelfand MS, Rodionov DA, Raffaelli N, Zhang H. 2009. Structure and function of an ADP-ribose-dependent transcriptional regulator of NAD metabolism. Structure 17: 939-951.
32. Hughes KT, Olivera BM, Roth JR. 1988. Structural gene for NAD synthetase in Salmonella typhimurium. J Bacteriol 170: 2113-2120.
33. Kang GB, Kim YS, Im YJ, Rho SH, Lee JH, Eom SH. 2005a. Crystal structure of NH3-dependent NAD+ synthetase from Helicobacter pylori. Proteins 58: 985-988.
34. Kang SJ, Park SJ, Jung SJ, Lee BJ. 2005b. Solution structure of HP1242 from Helicobacter pylori. Proteins 61: 1111-1113.
35. Kawai S, Murata K. 2008. Structure and function of NAD kinase and NADP phosphatase: Key enzymes that regulate the intracellular balance of NAD(H) and NADP(H). Biosci Biotechnol Biochem 72: 919-930.
36. Kawai S, Mori S, Mukai T, Matsukawa H, Matuo Y, Murata K. 2001. Establishment of a mass-production system for NADP using bacterial inorganic polyphosphate/ATP-NAD kinase. J Biosci Bioeng 92: 447-452.
37. Khan JA, Xiang S, Tong L. 2007. Crystal structure of human nicotinamide riboside kinase. Structure 15: 1005-1013.
38. Kim IK, Yim HS, Kim DW, Kim YM, Lee HS, Cha SS, Kang SO. 2004. Crystallization and preliminary X-ray crystallographic analysis of a ytfG gene product from Escherichia coli. Acta Crystallogr D Biol Crystallogr 60: 365-367.
39. Kornberg A, Pricer WE, Jr. 1950. On the structure of triphosphopyridine nucleotide. J Biol Chem 186: 557-567.
40. Krawczyk J, Kohl TA, Goesmann A, Kalinowski J, Baumbach J. 2009. From Corynebacterium glutamicum to Mycobacterium tuberculosis-Towards transfers of gene regulatory networks and integrated data analyses with MycoRegNet. Nucleic Acids Res 37: e97.
41. Kurnasov O, Goral V, Colabroy K, Gerdes S, Anantha S, Osterman A, Begley TP. 2003. NAD biosynthesis: Identification of the tryptophan to quinolinate pathway in bacteria. Chem Biol 10: 1195-1204.
42. LaRonde-LeBlanc N, Resto M, Gerratana B. 2009. Regulation of active site coupling in glutamine-dependent NAD(+) synthetase. Nat Struct Mol Biol 16: 421-429.
43. Lee HC. 2001. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu Rev Pharmacol Toxicol 41: 317-345.
44. Lu S, Smith CD, Yang Z, Pruett PS, Nagy L, McCombs D, Delucas LJ, Brouillette WJ, Brouillette CG. 2008. Structure of nicotinic acid mononucleotide adenylyltransferase from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun 64: 893-898.
45. Ma B, Pan SJ, Zupancic ML, Cormack BP. 2007. Assimilation of NAD(+) precursors in Candida glabrata. Mol Microbiol 66: 14-25.
46. Magni G, Di Stefano M, Orsomando G, Raffaelli N, Ruggieri S. 2009. NAD(P) biosynthesis enzymes as potential targets for selective drug design. Curr Med Chem 16: 1372-1390.
47. Manjunatha U, Boshoff H, Dowd C, Zhang L, Albert T, Norton J, Daniels L, Dick T, Pang S, Barry C. 2006. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci 103: 431.
48. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466.
49. Matsushita H, Yokoyama S, Obayashi A. 1986. NADP+ production using thermostable NAD+ kinase of corynebacterium flaccumfaciens AHU-1622. Can J Microbiol 32: 585-590.
50. Maxwell A. 1997. DNA gyrase as a drug target. Trends Microbiol 5: 102-109.
51. McDonald HM, Pruett PS, Deivanayagam C, Protasevich II, Carson WM, DeLucas LJ, Brouillette WJ, Brouillette CG. 2007. Structural adaptation of an interacting non-native C-terminal helical extension revealed in the crystal structure of NAD+ synthetase from Bacillus anthracis. Acta Crystallogr D Biol Crystallogr 63: 891-905.
52. Mori S, Yamasaki M, Maruyama Y, Momma K, Kawai S, Hashimoto W, Mikami B, Murata K. 2005. NAD-binding mode and the significance of intersubunit contact revealed by the crystal structure of Mycobacterium tuberculosis NAD kinase-NAD complex. Biochem Biophys Res Commun 327: 500-508.
53. Murphy DJ, Brown JR. 2008. Novel drug target strategies against Mycobacterium tuberculosis. Curr Opin Microbiol 11: 422-427.
54. Nessi C, Albertini AM, Speranza ML, Galizzi A. 1995. The outB gene of Bacillus subtilis codes for NAD synthetase. J Biol Chem 270: 6181-6185.
55. Olland AM, Underwood KW, Czerwinski RM, Lo MC, Aulabaugh A, Bard J, Stahl ML, Somers WS, Sullivan FX, Chopra R. 2002. Identification, characterization, and crystal structure of Bacillus subtilis nicotinic acid mononucleotide adenylyltransferase. J Biol Chem 277: 3698-3707.
56. Outten CE, Culotta VC. 2003. A novel NADH kinase is the mitochondrial source of NADPH in Saccharomyces cerevisiae. EMBO J 22: 2015-2024.
57. Poncet-Montange G, Assairi L, Arold S, Pochet S, Labesse G. 2007. NAD kinases use substrate-assisted catalysis for specific recognition of NAD. J Biol Chem 282: 33925-33934.
58. Preiss J, Handler P. 1958. Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects. J Biol Chem 233: 493-500.
59. Raffaelli N, Sorci L, Amici A, Emanuelli M, Mazzola F, Magni G. 2002. Identification of a novel human nicotinamide mononucleotide adenylyltransferase. Biochem Biophys Res Commun 297: 835-840.
60. Raffaelli N, Finaurini L, Mazzola F, Pucci L, Sorci L, Amici A, Magni G. 2004. Characterization of Mycobacterium tuberculosis NAD kinase: Functional analysis of the full-length enzyme by site-directed mutagenesis. Biochemistry 43: 7610-7617.
61. Rizzi M, Schindelin H. 2002. Structural biology of enzymes involved in NAD and molybdenum cofactor biosynthesis. Curr Opin Struct Biol 12: 709-720.
62. Rodionov DA, De Ingeniis J, Mancini C, Cimadamore F, Zhang H, Osterman AL, Raffaelli N. 2008a. Transcriptional regulation of NAD metabolism in bacteria: NrtR family of Nudix-related regulators. Nucleic Acids Res 36: 2047-2059.
63. Rodionov DA, Li X, Rodionova IA, Yang C, Sorci L, Dervyn E, Martynowski D, Zhang H, Gelfand MS, Osterman AL. 2008b. Transcriptional regulation of NAD metabolism in bacteria: Genomic reconstruction of NiaR (YrxA) regulon. Nucleic Acids Res 36: 2032-2046.
64. Rossolillo P, Marinoni I, Galli E, Colosimo A, Albertini AM. 2005. YrxA is the transcriptional regulator that represses de novo NAD biosynthesis in Bacillus subtilis. J Bacteriol 187: 7155-7160.
65. Sakai T, Morita Y, Araki T, Masuyama Y. 1997. Simple and rapid method for determining nicotinamide adenine dinucleotide synthetase activity by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 704: 77-81.
66. Sasaki H, Haraguchi Y, Itotani M, Kuroda H, Hashizume H, Tomishige T, Kawasaki M, Matsumoto M, Komatsu M, Tsubouchi H. 2006. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2, 3-dihydroimidazo [2, 1-b] oxazoles. J Med Chem 49: 7854-7860.
67. Sassetti CM, Rubin EJ. 2007. The open book of infectious diseases. Nat Med 13: 279-280.
68. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
69. Shindikar A, Viswanathan C. 2005. Novel fluoroquinolones: Design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg Med Chem Lett 15: 1803-1806.
70. Snider GL. 1997. Tuberculosis then and now: A personal perspective on the last 50 years. Ann Intern Med 126: 237-243.
71. Tempel W, Rabeh WM, Bogan KL, Belenky P, Wojcik M, Seidle HF, Nedyalkova L, Yang T, Sauve AA, Park HW, Brenner C. 2007. Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol 5: e263.
72. Tritz GJ, Chandler JL. 1973. Recognition of a gene involved in the regulation of nicotinamide adenine dinucleotide biosynthesis. J Bacteriol 114: 128-136.
73. Uhr ML, Smulson M. 1982. NMN adenylyltransferase: Its association with chromatin and with poly(ADP-ribose) polymerase. Eur J Biochem 128: 435-443.
74. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. 2009. New drugs against tuberculosis: Problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 53: 849-862.
75. Velu SE, Mou L, Luan CH, Yang ZW, DeLucas LJ, Brouillette CG, Brouillette WJ. 2007. Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: Amide- and ether-linked tethered dimers with alpha-amino acid end groups. J Med Chem 50: 2612-2621.
76. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK. 2003. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198: 705-713.
77. Wojcik M, Seidle HF, Bieganowski P, Brenner C. 2006. Glutamine-dependent NAD+ synthetase. How a two-domain, three-substrate enzyme avoids waste. J Biol Chem 281: 33395-33402.
78. Ying W. 2007. NAD+ and NADH in brain functions, brain diseases and brain aging. Front Biosci 12: 1863-1888.
79. Ying W. 2008. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: Regulation and biological consequences. Antioxid Redox Signal 10: 179-206.
80. Yoon HJ, Kim HL, Mikami B, Suh SW. 2005. Crystal structure of nicotinic acid mononucleotide adenylyltransferase from Pseudomonas aeruginosa in its Apo and substrate-complexed forms reveals a fully open conformation. J Mol Biol 351: 258-265.
81. You KS. 1985. Stereospecificity for nicotinamide nucleotides in enzymatic and chemical hydride transfer reactions. Crit Rev Biochem 17: 313-451.
82. Zerez CR, Wong MD, Tanaka KR. 1990. Partial purification and properties of nicotinamide adenine dinucleotide synthetase from human erythrocytes: Evidence that enzyme activity is a sensitive indicator of lead exposure. Blood 75: 1576-1582.
83. Zhang H, Zhou T, Kurnasov O, Cheek S, Grishin NV, Osterman A. 2002. Crystal structures of E. coli nicotinate mononucleotide adenylyltransferase and its complex with deamido-NAD. Structure 10: 69-79.
84. Zhang X, Kurnasov OV, Karthikeyan S, Grishin NV, Osterman AL, Zhang H. 2003. Structural characterization of a human cytosolic NMN/NaMN adenylyltransferase and implication in human NAD biosynthesis. J Biol Chem 278: 13503-13511.
85. Zhou T, Kurnasov O, Tomchick DR, Binns DD, Grishin NV, Marquez VE, Osterman AL, Zhang H. 2002. Structure of human nicotinamide/nicotinic acid mononucleotide adenylyltransferase. Basis for the dual substrate specificity and activation of the oncolytic agent tiazofurin. J Biol Chem 277: 13148-13154.
86. Zhu N, Roth JR. 1991. The nadI region of Salmonella typhimurium encodes a bifunctional regulatory protein. J Bacteriol 173: 1302-1310.